Search results for "NPH insulin"

showing 2 items of 2 documents

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1…

2012

OBJECTIVE We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change bet…

Blood GlucoseMaleEXENATIDEendocrine system diseasesdiabetes liraglutide metfortmin hypoglycemiaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesTHERAPYGastroenterologyMELLITUSInsulin DetemirGlucagon-Like Peptide 1GLYCEMIC CONTROLOriginal ResearchInsulin detemirAged 80 and overClinical Care/Education/Nutrition/Psychosocial ResearchTREATED PATIENTSMiddle AgedMetforminMetforminNPH INSULINInsulin Long-ActingFemaleLife Sciences & Biomedicinehormones hormone substitutes and hormone antagonistsmedicine.drugAdultmedicine.medical_specialtyPARALLEL-GROUPAdolescentmedicine.drug_classHypoglycemiaEndocrinology & MetabolismDiabetes mellitusInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsCOMBINATIONAgedGlycated HemoglobinAdvanced and Specialized NursingScience & TechnologyLiraglutidebusiness.industryInsulin26-WEEKnutritional and metabolic diseasesLiraglutideEFFICACYmedicine.diseaseSulfonylureaEndocrinologyDiabetes Mellitus Type 2business
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct